Therapies for Children With Autism Spectrum Disorders

23. Kanner L. Autistic Disturbances of
Affective Contact. Nervous Child 2. 1943
1943:217-250.
24. Rutter M. Diagnosis and definition of
childhood autism. J Autism Child
Schizophr. 1978 Jun;8(2):139-161.
25. Chalfant AM, Rapee R and Carroll L.
Treating anxiety disorders in children with
high functioning autism spectrum disorders:
a controlled trial. J Autism Dev Disord.
2007 Nov;37(10):1842-1857.
26. Reaven JA, Blakeley-Smith A, Nichols S, et
al. Cognitive-Behavioral Group Treatment
for Anxiety Symptoms in Children with
High-Functioning Autism Spectrum
Disorders: A Pilot Study. Focus on Autism
and Other Developmental Disabilities.
2009;24(1):27-37.
27. Reaven J and Hepburn S. Cognitivebehavioral
treatment of obsessivecompulsive
disorder in a child with
Asperger syndrome: a case report. Autism.
2003 Jun;7(2):145-164.
28. Muris P, Steerneman P, Merckelbach H, et
al. Comorbid anxiety symptoms in children
with pervasive developmental disorders. J
Anxiety Disord. 1998 Jul-Aug;12(4):387-
393.
29. Child and adolescent therapy : cognitivebehavioral
procedures. Kendall PC, editor.
New York: Guildford Press; 2005.
30. Mesibov GSV. The culture of autism: From
theoretical understanding to educational
practice. University of North Carolina at
Chapel Hill: Division TEACCH,
Department of Psychiatry; 1998.
31. Carpenter WT and Koenig JI. The evolution
of drug development in schizophrenia: past
issues and future opportunities.
Neuropsychopharmacology. 2008
Aug;33(9):2061-2079.
32. Akam E and Strange PG. Inverse agonist
properties of atypical antipsychotic drugs.
Biochem Pharmacol. 2004 Jun
1;67(11):2039-2045.
33. Meltzer HY and Huang M. In vivo actions
of atypical antipsychotic drug on
serotonergic and dopaminergic systems.
Prog Brain Res. 2008;172:177-197.
129
34. Kuroki T, Nagao N and Nakahara T.
Neuropharmacology of second-generation
antipsychotic drugs: a validity of the
serotonin-dopamine hypothesis. Prog Brain
Res. 2008;172:199-212.
35. Scherk H, Pajonk FG and Leucht S. Secondgeneration
antipsychotic agents in the
treatment of acute mania: a systematic
review and meta-analysis of randomized
controlled trials. Arch Gen Psychiatry. 2007
Apr;64(4):442-455.
36. Nelson JC and Papakostas GI. Atypical
antipsychotic augmentation in major
depressive disorder: a meta-analysis of
placebo-controlled randomized trials. Am J
Psychiatry. 2009 Sep;166(9):980-91.
37. Bloch MH, Landeros-Weisenberger A,
Kelmendi B, et al. A systematic review:
antipsychotic augmentation with treatment
refractory obsessive-compulsive disorder.
Mol Psychiatry. 2006 Jul;11(7):622-632.
38. Bloch MH. Emerging treatments for
Tourette’s disorder. Curr Psychiatry Rep.
2008 Aug;10(4):323-30.
39. Anderson LT, Campbell M, Adams P, et al.
The effects of haloperidol on discrimination
learning and behavioral symptoms in autistic
children. J Autism Dev Disord. 1989
Jun;19(2):227-239.
40. Tatsumi M, Groshan K, Blakely RD, et al.
Pharmacological profile of antidepressants
and related compounds at human
monoamine transporters. Eur J Pharmacol.
1997 Dec 11;340(2-3):249-258.
41. Esbensen AJ, Greenberg JS, Seltzer MM, et
al. A longitudinal investigation of
psychotropic and non-psychotropic
medication use among adolescents and
adults with autism spectrum disorders. J
Autism Dev Disord. 2009 Sep;39(9):1339-
1349.
42. Aman MG, Lam KS and Van Bourgondien
ME. Medication patterns in patients with
autism: temporal, regional, and demographic
influences. J Child Adolesc
Psychopharmacol. 2005 Feb;15(1):116-126.